Research coming out of the United Kingdom has identified that naringenin, a component of citrus fruits, successfully blocks the formation of kidney cysts. ![](/FileUploads/image/oranges.jpg)
![](/FileUploads/image/oranges.jpg)
Polycystic kidney disease, which causes the cysts, is an inherited disorder that leads to the loss of kidney function, high blood pressure, and dialysis. There are few treatment options available.The research team's discovery could be the next step in a cure.
“This discovery provides an important step forward in understanding how polycystic kidney disease may be controlled,” said Professor Robin Williams from the School of Biological Sciences at Royal Holloway.
The discovery was tested using a mammalian kidney cell-line, in which the team triggered the formation of cysts. They were able to block the cysts by adding naringenin. Ultimately, the research revealed that naringenin could regulate PKD2 levels, the protein responsible for polycystic kidney disease, and successfully block the formation of cysts.
The findings were published in the British Journal of Pharmacology. Research was conducted by a team of scientists from Royal Holloway, St. George’s, University of London and Kingston University London. The research was funded by a SWan (SouthWest London Academic Network) research grant.
For more information visit the Royal Holloway website.
Latest from Greenhouse Management
- Ken and Jean Royer Family Fund through American Floral Endowment provides travel grants for retail florists
- Sun Gro Horticulture launches climate-conscious potting mix Sunshine Black Bear
- Dümmen Orange North America hires regional product manager for perennials
- Justin Wisniewski named general manager of Must Have Perennials
- J. Berry Nursery grows community connections with plants
- Judge upholds $1.89 million penalty against Agro Research International for adulteration, mislabeling of organic fertilizer
- Registration now open for the 2024 GLASE Summit
- Curoplant Company Ltd. changes name to Bloomin’ Easy Plants Inc.